Neuro-oncology of neurofibromatosis type 1

Current Treatment Options in Neurology

Volumn 11, Issue 4, 2009, Pages 306-314

  Hottinger, Andreas F ^a   Khakoo, Yasmin ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; ATAZANAVIR; BEVACIZUMAB; CARBOPLATIN; DIGOXIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORODEOXYGLUCOSE; IRINOTECAN; KETOCONAZOLE; LOMUSTINE; MONOCLONAL ANTIBODY; PHENYTOIN; PIRFENIDONE; PROCARBAZINE; RAPAMYCIN; TEMOZOLOMIDE; TIOGUANINE; TIPIFARNIB; VINCRISTINE;

ABDOMINAL PAIN; ACNE; ALOPECIA; ANEMIA; APPLICATION SITE PHOTOSENSITIVITY REACTION; ARTERY THROMBOSIS; ARTHRALGIA; AUTONOMIC NEUROPATHY; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER GRADING; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG INHIBITION; DRUG POTENTIATION; EARLY DIAGNOSIS; FATIGUE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GLIOMA; GOUT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERICUM PERFORATUM; HYPERTENSION; HYPERURICEMIA; MAINTENANCE THERAPY; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; NAUSEA; NEPHROTIC SYNDROME; NERVE SHEATH TUMOR; NEUROFIBROMA; NEUROFIBROMATOSIS; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE GLIOMA; PERIPHERAL EDEMA; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATION; RADIATION INJURY; RASH; REVIEW; SECOND CANCER; SIDE EFFECT; STEREOTACTIC BIOPSY; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION; URIC ACID NEPHROPATHY; URINARY TRACT INFECTION; VEIN THROMBOSIS; VOMITING; WEAKNESS;

EID: 66749153729     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-009-0034-4     Document Type: Review

References (31)

1. Walker L, Thompson D, Easton D, et al.: A prospective study of neurofibromatosis type 1 cancer incidence in the UK. Br J Cancer 2006, 95:233-238.
2. Gutmann DH: The nWurofibromatoses: when less is more. Hum Mol Genet 2001, 10:747-755.
3. Williams VC, Lucas J, Babcock MA, et al.: Neurofibromatosis type 1 revisited. Pediatrics 2009, 123:124-133.
4. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 1988, 45:575-578.
5. Ferner RE, Huson SM, Thomas N, et al.: Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 2007, 44:81-88.
6. Packer RJ, Gutmann DH, Rubenstein A, et al.: Plexiform neurofibromas in NF1: Toward biologic-based therapy. Neurology 2002, 58:1461-1470.
7. Matsumine A, Kusuzaki K, Nakamura T, et al.: Differentiation between neurofibromas and malignant peripheral nerve sheath tumors in neurofibromatosis 1 evaluated by MRI. J Cancer Res Clin Oncol 2008 Dec 20 (Epub ahead of print).
8. Woodruff JM, Chernik NL, Smith MC, et al.: Peripheral nerve tumors with rhabdomyosarcomatous differentiation (malignant "Triton" tumors). Cancer 1973, 32:426-439.
9. Viskochil DH: It Makes two to tango: mast cell and Schwann cell interactions in neurofibromas. J Clin Invest 2003, 112:1791-1793.
10. Friedrich RE, Schmelzle R, Hartmann M, Mautner VF: Subtotal and total resection of superficial plexiform neurofibromas of face and neck: Four case reports. J Craniomaxillofac Surg 2005, 33:55-60.
11. Widemann BC, Salzer WL, Arceci RJ, et al.: Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J Clin Oncol 2006, 24:507-516.
12. Babovic-Vuksanovic D, Ballman K, Michels V, et al.: Phase II trial of pirfenidone in adults with neurofibromatosis type 1. Neurology 2006, 67:1860-1862.
13. Evans DG, Baser ME, McGaughran J, et al.: Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 2002, 39:311-314.
14. King AA, Debaun MR, Riccardi VM, Gutmann DH: Malignant peripheral nerve sheath tumors in neurofibromatosis 1. Am J Med Genet 2000, 93:388-392.
15. Fisher MJ, Basu S, Dombi E, et al.: The role of [18F]-fluorodeoxyglucose positron emission tomography in predicting plexiform neurofibroma progression. J Neurooncol 2008, 87:165-171.
16. Ferner RE, Golding JF, Smith M, et al.: [18F] 2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): A long-term clinical study. Ann Oncol 2008, 19:390-394.
17. Brenner W, Friedrich RE, Gawad KA, et al.: Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours. Eur J Nucl Med Mol Imaging 2006, 33:428-432.
18. Gachiani J, Kim D, Nelson A, Kline D: Surgical management of malignant peripheral nerve sheath tumors. Neurosurg Focus 2007, 22:E13.
19. Carli M, Ferrari A, Mattke A, et al.: Pediatric malignant peripheral nerve sheath tumor: The Italian and German Soft Tissue Sarcoma Cooperative Group. J Clin Oncol 2005, 23:8422-8430.
20. Tabone-Eglinger S, Bahleda R, Côté JF, et al.: Frequent EGFR positivity and overexpression in high-grade areas of human MPNSTs. Sarcoma 2008, 2008: 849156.
21. Lewis RA, Gerson LP, Axelson KA, et al.: Von Recklinghausen neurofibromatosis. II. Incidence of optic gliomata. Ophthalmology 1984, 91:929-935.
22. Jahraus CD, Tarbell NJ: Optic pathway gliomas. Pediatr Blood Cancer 2006, 46:586-596.
23. King A, Listernick R, Charrow J, et al.: Optic pathway gliomas in neurofibromatosis type 1: The effect of presenting symptoms on outcome. Am J Med Genet A 2003, 122:95-99.
24. Listernick R, Ferner RE, Liu GT, Gutmann DH: Optic pathway gliomas in neurofibromatosis-1: Controversies and recommendations. Ann Neurol 2007, 61:189-198.
25. Astrup J: Natural history and clinical management of optic pathway glioma. Br J Neurosurg 2003, 17:327-335.
26. Packer RJ, Ater J, Allen J, et al.: Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 1997, 86:747-754.
27. Jenkin D, Angyalfi S, Becker L, et al.: Optic glioma in children: surveillance, resection, or irradiation? Int J Radiat Oncol Biol Phys 1993, 25:215-225.
28. Singhal S, Birch JM, Kerr B, et al.: Neurofibromatosis type 1 and sporadic optic gliomas. Arch Dis Child 2002, 87:65-70.
29. Packer RJ, Jakacki R, Horn M, et al.: Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer 2009, 52:791-795.
30. Leonard JR, Perry A, Rubin JB, et al.: The role of surgical biopsy in the diagnosis of glioma in individuals with neurofibromatosis-1. Neurology 2006, 67:1509-1512.
31. Stupp R, Mason WP, van den Bent MJ, et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.